Сравнительная клинико-микробиологическая и фармакоэкономическая эффективность цефиксима и ципрофлоксацина при остром неосложненном цистите
Диссертация
Вместе с тем следует отметить, что в последние годы отмечается рост устойчивости уропатогенной кишечной палочки к фторхинолонам, которые рассматриваются в качестве препаратов выбора при лечении инфекций мочевыводящих путей, включая острый цистит. В ряде регионов Российской Федерации доля таких штаммов достигает 10%, что обусловливает потребность в использовании альтернативных препаратов… Читать ещё >
Список литературы
- Белоусов Ю. Б. Основы фармакоэкономических исследований / Ю. Б. Белоусов, Д. Ю. Белоусов, В. П. Комарова. М.: ООО «Издательство ОКИ», 2000. —87 с.
- Клинико-экономический анализ / П. А. Воробьев и др.- под ред. П. А. Воробьева. — М.: Ныодиамед, 2008. — 778 с.
- Гиляревский С.Р. Современные принципы анализа экономической эффективности медицинских вмешательств / С. Р. Гиляревский // Экономика здравоохранения. -2001. № 9. — С. 19−22.
- Гриднев О.В. Клинико-фармакологические аспекты рациональной антибиотикотерапии инфекций мочевыводящих путей: автореф. дисс. канд. мед. наук / О.В. Гриднев- Ставропольская мед. акад. Ставрополь, 2006. — 26 с.
- Антибактериальная терапия неосложненного острого цистита и пиелонефрита у взрослых. Пособие для врачей / H.A. Лопаткин и др. // Клиническая микробиология и антимикробная химиотерапия.- 2000. -№ 1.- С. 69−76.
- Лоран О.Б. Эпидемиологические аспекты инфекций мочевыводящих путей / О. Б. Лоран // Материалы симпозиума «Инфекции мочевыводящих путей у амбулаторных больных». Москва. — 1999. — С. 5−8.
- Новоселова Е. Дженерики без границ // Доступно на сайте: http://www.biorf.ru/catalog.aspx?catid=394&dno= 1593
- Петров В.И. Общая фармакоэкономика / В. И. Петров // Прикладная фармакоэкономика / В. И. Петров. М.: «ГЭОТАР-Медиа», 2005. — С. 7−35.
- Рафальский В.В. Антибиотикорезистентность фактор, определяющий выбор антимикробных препаратов для терапии инфекций мочевыводящий путей / В. В. Рафальский // Врачебное сословие.- 2004.- № 4, — С. 10−18.
- Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации к пероральному цефлоспорину IIIпоколения цефиксиму / В. В. Рафальский и др. // Лечащий врач.- 2008, — № 8.-С. 27−29.
- Резистентность возбудителей неосложненных инфекций мочевых путей в России / В. В. Рафальский и др. // Урология. 2006. — № 5. — С. 34−37.
- Резистентность возбудителей амбулаторных инфекций мочевыводящих путей по данным многоцентровых микробиологических исследований UTIAP-I и UTIAP-II / В. В. Рафальский и др. // Урология.- 2004.- № 2.- С. 1317.
- Рохликов И.М. Клинико-микробиологическая и фармакоэпидемиологическая характеристика внебольничных инфекций мочевыводящих путей в г. Москве: дисс. канд. мед. наук. / И.М. Рохликов- Смоленская гос. мед. акад. Смоленск, 2006.- 196 с.
- Al-Tawfiq J.A. Antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infections in a Saudi Arabian hospital / Al-Tawfiq J.A., Anani A.A.//Chemotherapy. 2009. — V. 55.-P. 127−131.
- Aronson J.K. et. al. Ciprofloxacin / In: Meyler’s side effects of drugs. The international encyclopedia of adverse drug reactions and interactions // Aronson J.K. editor. Oxford: Elsevier B.V., 2006. — P. 783−789.
- Asbach H.W. Single dose oral administration of cefixime 400 mg in the treatment of acute uncomplicated cystitis and gonorrhoea / Asbach H.W. // Drugs. 1991.-Vol. 42.-P. 10−13.
- Bachelier C.D. Urinary tract infections / Bachelier C.D., Bernstein J.M. // Med Clin North Am. 1997. Vol.81. — P. 719−730.
- Barry H.C. Evaluation of suspected urinary tract infection in ambulatory women: A cost-utility analysis of office-based strategies / Barry H.C., Ebell M.H., Hickner J. // J Fam Pract. -1997. Vol. 44. — P. 49−60.
- Barry A.L. Cefixime: Spectrum of antibacterial activity against 16,016 clinical isolates / Barry A.L., Jones R.N. // The Pediatric infectious disease journal. -1987.-Vol. 6.-P. 954−957.
- Serum protein binding of a new oral cephalosporin, cl 284,635, in various species / Bialer M. et. al. // Drug metabolism and disposition: the biological fate of chemicals.-1986. -Vol. 14.-P. 132−136.
- Brogden R.N. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential / Brogden R.N., Campoli-Richards D.M. // Drugs. 1989. — Vol. 38. — P. 524−550.
- Car J. Urinary tract infections in women: Diagnosis and management in primary care / Car J. // BMJ. 2006. — Vol. 332. — P. 94−97.
- A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections / Ceran N. et. al. // J Infect Chemother. 2010. — Vol. 16(6). — P. 424−30
- Chapman S.T. Prescribing in pregnancy. Bacterial infections in pregnancy / Chapman S.T. // Clin Obstet Gynaecol. 1986. — Vol. 13. — P. 397−416.
- Crump B. Pharmacokinetics and tissue penetration of ciprofloxacin / Crump B., Wise R., Dent J. // Antimicrob Agents Chemother. 1983. — Vol. 24. — P. 784 786.
- Cunningham F.G. Urinary tract infections complicating pregnancy / Cunningham F.G., Lucas M.J. // Baillieres Clin Obstet Gynaecol. 1994. — Vol. 8. -P. 353−373.
- Czaja C.A. Update on acute uncomplicated urinary tract infection in women / Czaja C.A., Hooton T.M. // Postgrad Med. 2006. — Vol. 119. — P. 39−45.
- Pharmacokinetics of three oral formulations of ciprofloxacin / Davis R.L. et. al. // Antimicrob Agents Chemother. 1985. — Vol. 28. — P. 74−77.
- Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: A comparison of two surveys with a 5 year interval / den Heijer C.D. et. al. // J Antimicrob Chemother. 2010. — Vol. 65. -P. 2128−2133.
- Urinary tract infection and adverse outcome of pregnancy / Dimetry S.R. et al. // J. Egypt. Public Health Assoc. 2007. — V. 82. — P. 203−218.
- Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment / Ernst E.J. et al. // Health Qual. Life Outcomes. -2005.-V. 3.-P. 45.
- Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. / Faulkner R.D. et al. // Journal of Clinical Pharmacology. 1987a. -Vol. 27.-P. 807−812.
- Absolute bioavailability of cefixime in men / Faulkner R.D. et al. // Journal of Clinical Pharmacology. 1988d. — Vol. 28. — P. 700−706.
- Pharmacokinetic profile of cefixime in man / Faulkner R.D. et al. // Pediatric Infectious Disease. 1987b. — Vol. 6. — P. 963−970.
- Fihn S.D. Clinical practice. Acute uncomplicated urinary tract infection in women / Fihn S.D. // N. Engl. J. Med. 2003. — Vol. 349. — P. 259−266.
- Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs / Foxman B. // Am. J. Med. 2002. — Vol. 113. — P. 5−13.
- Foxman B. Epidemiology of urinary tract infections: Transmission and risk factors, incidence, and costs / Foxman B., Brown P. // Infect. Dis. Clin. North. Am. -2003.-Vol. 17.-P. 227−241.
- Foxman B. Epidemiology of urinary tract infection: Ii. Diet, clothing, and urination habits / Foxman B., Frerichs R.R. // Am. J. Public Health. 1985. — Vol. 75.-P. 1314−1317.
- Gillenwater J.Y. Inflammatory diseases of the bladder / Gillenwater J.Y. // In Adult and pediatric urology / Sant G.R., editor, Philadelphia: Lippincott Williams & Wilkins, 2002. — P. 725−740.
- Goldman M.P. Antibacterial treatment strategies in hospitalized patients: What role for pharmacoeconomics? / Goldman M.P., Nair R. // Cleve Clin J Med. 2007. — Vol. 74. — Suppl. 4. — S. 38−47.
- Goldstein F.W. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre study group / Goldstein F.W. // Eur J Clin Microbiol Infect Dis. 2000. — Vol. 19. -P. 112−117.
- Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers / Gonzalez MA et. al. Antimicrob Agents Chemother. 1984. — Vol. 26.-P. 741−744.
- Guidelines on urological infections / Grabe M. et. al. European Association of Urology. — 2010.
- Griebling T.L. Urinary tract infection in women / Griebling T.L. // In Urologic diseases in America / Litwin M.S., Saigal C.S. editors, Washington, D.C.: US Government Publishing Office, 2004. — P. 153−183.
- Guay D.R. Contemporary management of uncomplicated urinary tract infections / Guay D.R. // Drugs. 2008. — Vol. 68. — P. 1169−1205.
- Pharmacokinetics of cefixime (cl 284,635-fk 027) in healthy subjects and patients with renal insuffiency / Guay D. et. al. // Antimicrobial Agents and Chemotherapy. 1986. — Vol. 30. — P. 485−490.
- Influence of ar/mg-containing antacids (a) on the pharmacokinethiks (pk) of cefixime© / Healy D. et. al. // Clinical Pharmacology and Therapeutics. 1989. -Vol. 45.-P. 164.
- Hedman P. Urinary tract infections caused by Staphylococcus saprophyticus. A matched case control study / Hedman P., Ringertz O. // J. Infect. 1991. — V. 23.-P. 145−153.
- A prospective study of risk factors for symptomatic urinary tract infection in young women / Hooton T.M. et al. // N. Engl. J. Med. 1996. — V. 335. — P. 468 474.
- Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: A randomized trial / Hooton T.M. et. al. // JAMA. 2005. -Vol. 293.-P. 949−955.
- Hooton T.M. Diagnosis and treatment of uncomplicated urinary tract infection / Hooton T.M., Stamm W.E. // Infect. Dis. Clin. North. Am. 1997. — V. 11.-P. 551−581.
- Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women / Hooton T.M. et. al. // JAMA. 1995.-Vol. 273.-P. 41−45.
- Johnson J.R. Diagnosis and treatment of acute urinary tract infections / Johnson J.R., Stamm W.E. // Infect Dis Clin North Am. 1987. — Vol. 1. — P. 773 791.
- Economic evaluation of an updated guideline for the empiric treatment of uncomplicated urinary tract infection in women / Kahan N.R. et. al. // Isr Med Assoc J. 2004. — Vol. 6. — P. 588−591.
- Clinical experience with Cefixime in urinary tract infections / Kameoka H. et. al. // The Japanese journal of antibiotics. 1989. — Vol. 42. — P. 2540−2547.
- Antimicrobial susceptibility of community-acquired uropathogens in general practice / Keah S. et al. // Malaysian Family Physician. 2007. — V. 2. — P. 6469.
- Latham R.H. Urinary tract infections in young adult women caused by Staphylococcus saprophyticus / Latham R.H., Running K., Stamm W.E. // JAMA. 1983. -V. 250. — P. 3063−3066.
- Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin / Ledergerber B. et. al. // Antimicrob Agents Chemother. 1985. — Vol. 27. — P. 350−352.
- Lederle Laboratories d.o.f.
- Cefixime penetration in human renal parenchyma / Leroy A. et. al. // Antimicrobial agents and chemotherapy. 1995. — Vol. 39. — P. 1240−1242.
- Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections / Manges A.R. et al. // Emerg. Infect. Dis. 2008. — V. 14. — P. 15 751 583.
- Antimicrobial resistance surveillance among commensal Escherichia coli in rural and urban areas in southern India / Mathai E. et al. // Trop. Med. Int. Health. -2008. V. 13.-P. 41−45.
- Matsumoto T. 2008 nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan / Matsumoto T. // Int. J. of Antimicrob. Agents. 2009. — V. 34. — P. S37.
- Comparative activities of ciprofloxacin (bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid / Muytjens H.L. et. al. // Antimicrob Agents Chemother. 1983. — Vol. 24.-P. 302−304.
- Naber K. EAU guidelines for the management of urinary and male genital tract infections / Naber K., Bjerklund-Johansen T., Bishop M. European Association of Urology. — 2006. — PP. 126.
- Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): Implications for empiric therapy / Naber K.G. et al. // Eur. Urol. 2008. — V. 54. — P. 1164−1178.
- Neu H.C. In vitro activity of a new broad spectrum b-lactamase-stable oral cefalosporin, cefixime / Neu H.C. // Pediatric Infectious Disease. 1987. — Vol. 6. -P. 958−962.
- Nicolle L. Epidemiology of urinary tract infections / Nicolle L. // Clinical Microbiology Newsletter. 2002. — V. 24. — P. 135−140.
- Turbidometric studies of the effect of fk027 on the growth of aerobic and anaerobic bacteria / O’Grady F.W. et. al. // 14th International Congress of Chemotherapy, Kyoto. 23−28 June 1985. — Japan Convention Services, INC 1985.
- Olson R.P. Antibiotic resistance to Escherichia coli in urinary isolates from college women with urinary tract infections / Olson R.P., Harrell L.J., Kaye K.S. // Antimicrob. Agents Chemother. 2009. -V. 53. P. 1285−1286.
- Antimicrobial resistance profiles of community-acquired uropathogenic Escherichia coli isolates during 2004−2006 in a training hospital in Istanbul / Ozyurt M. et al. // Mikrobiyol. Bui. 2008. — V. 42. — P. 231−243.
- Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and other uropathogens in northern Israel (1995−2005) / Rock W. et al. // Isr. Med. Assoc. J. 2007. — V. 9. — P. 803−805.
- Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections / Rosenberg M. // Int J Antimicrob Agents. 1999. — Vol. 11. — P. 247 251- discussion 261−244.
- Saito A. Pharmacokinetic studies of Cefixime / Saito A. // Chemotherapy. -1985.-Vol. 33.-P. 190−203.
- Evolution of Escherichia coli antibiotic resistances in urine samples from the community / Sanchez Merino J.M. et. al. // Arch Esp Urol. 2008. — Vol. 61. -P. 776−780.
- The diagnosis of urinary tract infection: A systematic review / Schmiemann G. et. al. // Dtsch Arztebl Int. 2010. — Vol. 107. — P. 361−367.
- Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women / Sheinfeld J. et al. // N. Engl. J. Med. 1989. — V. 320. — P. 773−777.
- Safety profile of Cefixime / Tally F. et. al. // Pediatric Infectious Disease. -1987.-Vol. 6.-P. 976−980.
- Tanagho E.A. Bacterial infections of the genitourinary tract / Tanagho E.A., McAninch J.W. // In: Smith’s general urology / Tanagho E.A., McAninch J.W., editors. San Francisco: The McGraw-Hill Companies, 2007. — P. 269−301.
- Cost effectiveness of management strategies for urinary tract infections: Results from randomised controlled trial / Turner D. et. al. // BMJ. 2010. — Vol. 340.-c. 346
- Clinical urinary tract isolates of Enterobacteriaceae in the Arkhangelsk region, Russia: Antimicrobial resistance profiles and characterization of ESBL-strains / Vorobieva V. et al. // 17th ECCMID/25th ICC March 31 April 3, 2007, Munich, Germany.
- Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. IDSA / Warren J.W. et al. // Clin. Infect. Dis. 1999. — V. 29. — P. 745−758.
- Antibiotic resistance in Escherichia coli outpatient urinary isolates: Final results from the North American urinary tract infection collaborative alliance (NAUTICA) / Zhanel G.G. et al. // Int. J. Antimicrob. Agents. 2006. — V. 27. -P. 468−475.